These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 12736115)
1. Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients. Scartozzi M; De Nictolis M; Galizia E; Carassai P; Bianchi F; Berardi R; Gesuita R; Piga A; Cellerino R; Porfiri E Eur J Cancer; 2003 May; 39(8):1144-9. PubMed ID: 12736115 [TBL] [Abstract][Full Text] [Related]
2. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Samimi G; Fink D; Varki NM; Husain A; Hoskins WJ; Alberts DS; Howell SB Clin Cancer Res; 2000 Apr; 6(4):1415-21. PubMed ID: 10778972 [TBL] [Abstract][Full Text] [Related]
3. Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients. Magnowska M; Surowiak P; Nowak-Markwitz E; Michalak M; Magnowski P; Rokita W; Kedzia H; Zabel M; Spaczyński M Ginekol Pol; 2008 Dec; 79(12):826-34. PubMed ID: 19175039 [TBL] [Abstract][Full Text] [Related]
4. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776 [TBL] [Abstract][Full Text] [Related]
5. Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. Scartozzi M; Franciosi V; Campanini N; Benedetti G; Barbieri F; Rossi G; Berardi R; Camisa R; Silva RR; Santinelli A; Ardizzoni A; Crinò L; Rindi G; Cascinu S Lung Cancer; 2006 Jul; 53(1):103-9. PubMed ID: 16716446 [TBL] [Abstract][Full Text] [Related]
6. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Strathdee G; MacKean MJ; Illand M; Brown R Oncogene; 1999 Apr; 18(14):2335-41. PubMed ID: 10327053 [TBL] [Abstract][Full Text] [Related]
7. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525 [TBL] [Abstract][Full Text] [Related]
9. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer. Zhang H; Zhang S; Cui J; Zhang A; Shen L; Yu H Aust N Z J Obstet Gynaecol; 2008 Oct; 48(5):505-9. PubMed ID: 19032668 [TBL] [Abstract][Full Text] [Related]
10. Hsp27, Hsp70 and mismatch repair proteins hMLH1 and hMSH2 expression in peripheral blood lymphocytes from healthy subjects and cancer patients. Nadin SB; Vargas-Roig LM; Drago G; Ibarra J; Ciocca DR Cancer Lett; 2007 Jul; 252(1):131-46. PubMed ID: 17276589 [TBL] [Abstract][Full Text] [Related]
11. Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer. Kitajima Y; Miyazaki K; Matsukura S; Tanaka M; Sekiguchi M Gastric Cancer; 2003; 6(2):86-95. PubMed ID: 12861399 [TBL] [Abstract][Full Text] [Related]
12. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Gifford G; Paul J; Vasey PA; Kaye SB; Brown R Clin Cancer Res; 2004 Jul; 10(13):4420-6. PubMed ID: 15240532 [TBL] [Abstract][Full Text] [Related]
13. Loss of DNA mismatch repair in acquired resistance to cisplatin. Aebi S; Kurdi-Haidar B; Gordon R; Cenni B; Zheng H; Fink D; Christen RD; Boland CR; Koi M; Fishel R; Howell SB Cancer Res; 1996 Jul; 56(13):3087-90. PubMed ID: 8674066 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of hMLH1 and hMSH2 proteins in serous ovarian tumours. Stasikowska-Kanicka O; Stawerski P; Wagrowska-Danilewicz M; Danilewicz M Pol J Pathol; 2009; 60(4):174-8. PubMed ID: 20072951 [TBL] [Abstract][Full Text] [Related]
15. Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer. Murata H; Khattar NH; Gu L; Li GM Cancer Lett; 2005 Jun; 223(1):143-50. PubMed ID: 15890247 [TBL] [Abstract][Full Text] [Related]
16. Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors. Olasz J; Mándoky L; Géczi L; Bodrogi I; Csuka O; Bak M Anticancer Res; 2005; 25(6B):4319-24. PubMed ID: 16309235 [TBL] [Abstract][Full Text] [Related]
17. Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression. Scartozzi M; Bianchi F; Rosati S; Galizia E; Antolini A; Loretelli C; Piga A; Bearzi I; Cellerino R; Porfiri E J Clin Oncol; 2002 Mar; 20(5):1203-8. PubMed ID: 11870161 [TBL] [Abstract][Full Text] [Related]
18. BAT-26 microsatellite instability does not correlate with the loss of hMLH1 and hMSH2 protein expression in sporadic endometrial cancers. Miturski R; Bogusiewicz M; Tarkowski R; Ciotta C; Bignami M; Burnouf D; Jakowicki JA Oncol Rep; 2003; 10(4):1039-43. PubMed ID: 12792767 [TBL] [Abstract][Full Text] [Related]
19. Transient mismatch repair gene transfection for functional analysis of genetic hMLH1 and hMSH2 variants. Brieger A; Trojan J; Raedle J; Plotz G; Zeuzem S Gut; 2002 Nov; 51(5):677-84. PubMed ID: 12377806 [TBL] [Abstract][Full Text] [Related]
20. Microsatellite instability and hMLH1 and hMSH2 expression analysis in soft tissue sarcomas. Kawaguchi K; Oda Y; Takahira T; Saito T; Yamamoto H; Kobayashi C; Tamiya S; Oda S; Iwamoto Y; Tsuneyoshi M Oncol Rep; 2005 Feb; 13(2):241-6. PubMed ID: 15643505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]